¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tissue survival"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® five-year survival rate ÇÑ±Û ¿À³â»ýÁ¸À²
¼³¸í   
  1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü È¤Àº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀǠǥÇö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ Àִ »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
¿µ¹® connective tissue ÇÑ±Û °áÇÕÁ¶Á÷
¼³¸í   
  Ã¼³»¿¡ ³Î¸® ºÐÆ÷Çϸç, Àå±â, Á¶Á÷»çÀ̸¦ ¸Þ¿ì°í ±×°ÍÀ» ±â°èÀûÀ¸·Î ÁöÁö, Á¶Á÷ÀÌ´Ù. ±×¹Û¿¡ Ç÷°ü, ¸²ÇÁ°ü, ½Å°æÀ» ÀεµÇϸ砿µ¾ç, ´ë»ç»ê¹°ÀÇ ¼ö¼Û ¶Ç´Â Àú·ù, ³ª¾Æ°¡¼­´Â ¼Õ»ó, °¨¿°¿¡ ´ëÇÑ ¹æ¾î ¶Ç´Â ¼öº¹ µî¿¡µµ ÀÛ¿ëÇÑ´Ù. °áÇÕÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀ̠dzºÎÇϸç, ¼¼Æ÷°£ÁúÀ» ±¸¼ºÇϴ ±âÁú°ú ¼¶À¯ÀÇ ¼º»ó¿¡ µû¶ó °£¿±Á¶Á÷, ¼¶À¯¼º °áÇÕÁ¶Á÷(¼º±ä¼¶À¯¼º °áÇÕÁ¶Á÷, ÃÎÃÎÇÑ ¼¶À¯¼º °áÇÕÁ¶Á÷), Áö¹æÁ¶Á÷, Åº¼ºÁ¶Á÷, ¼¼¸Á Á¶Á÷ µîÀ¸·Î ºÐ·ùµÈ´Ù.
  
  
¿µ¹® osseous tissue ÇÑ±Û »ÀÁ¶Á÷, °ñÁ¶Á÷
¼³¸í   
  °ñ¼¼Æ÷¿Í °ñ¼¼Æ÷ÁÖÀ§ÀÇ µüµüÇÑ Ä®½·Á¶Á÷À¸·Î µÑ·¯½ÎÀΠ¹ÐÁýµÈ °áÇÕÁ¶Á÷À» ¶æÇÑ´Ù. ÀÌ °ñÁ¶Á÷¿¡ ÀÇÇØ¼­ »À°¡ ÀÌ·ç¾îÁ® ÀÎüÀÇ °ñ°ÝÀ» Çü¼ºÇÑ´Ù.
¿µ¹® epithelial tissue ÇÑ±Û »óÇÇÁ¶Á÷
¼³¸í   
  »óÇǴ ÇÑ Ãþ ¶Ç´Â ¿©·¯ ÃþÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁø ÆÇ ¸ð¾çÀÇ ±¸Á¶·Î ½ÅüÀǠǥ¸é°ú °ü»ó±¸Á¶ÀÇ ³»°­À» µÑ·¯½Î°í ÀÖ´Ù. »óÇǼ¼Æ÷¿Í »óÇǼ¼Æ÷»çÀÌÀÇ ÀûÀº ¾çÀ¸·Î Á¸ÀçÇÏ¿© »óÇÇ»çÀÌÀÇ °ø°£À» Ã¤¿ì°í Àִ ¼¼Æ÷°£ÁúÀ» ÇÕÃÄ »óÇÇÁ¶Á÷À̶ó ÇÑ´Ù. »óÇÇÁ¶Á÷¿¡´Â ¿øÄ¢ÀûÀ¸·Î Ç÷°üÀÌ ºÐÆ÷µÇ¾î ÀÖÁö ¾Ê´Ù.
¿µ¹® granulation tissue ÇÑ±Û À°¾ÆÁ¶Á÷
¼³¸í   
  ¸ð¼¼Ç÷°üÀ̠dzºÎÇϸ砿ռºÇϰԠÁõ½ÄÀ» °è¼ÓÇϴ ¾î¸° °áÇÕÁ¶Á÷. Ã¢»ó µî Á¶Á÷ °á¼Õ¿¡ ´ëÇÑ ¼öº¹, À̹°Ã³¸®ÀÇ ±âÁúÈ­, ¿°ÁõÀÌ ¸¸¼ºÀûÀΠ°æ°ú¿¡ Àְųª Á¾¾çÁõ½Ä¿¡ µ¿¹ÝµÈ »çÀ̹°ÁúÀÇ ¹ÝÀÀ¼º ¿°Áõ¿¡¼­ °üÂûµÈ´Ù. ±¸¼º¼ººÐÀº »ý±äÁö ¾ó¸¶ ¾ÈµÇ´Â ¾î¸° À°¾ÆÁ¶Á÷Àº ¼¶À¯¸ð¼¼Æ÷ÀÇ Áõ½Ä, »õ·Î »ý±ä ¸ð¼¼Ç÷°ü°ú ¿©·¯ À¯ÁÖ¼¼Æ÷ ¹× ´Ù¸¥ Áß°£¿±¼¼Æ÷(¹éÇ÷±¸, ¸²ÇÁ±¸, ÇüÁú¼¼Æ÷, Á¶Á÷±¸, ´ÜÇÙ±¸, °Å´ë¼¼Æ÷)µîÀ¸·Î ±¸¼ºµÈ´Ù. À̰ÍÀÌ ½Ã°£ÀÌ Áö³ª ±×¸®µÇ¸é, ¸ð¼¼Ç÷°ü°ú À¯ÁÖ¼¼·Î, ´Ù¸¥Á¶Á÷¼ººÐÀ» °¨¼Ò½ÃÄÑ ¸¸¼ºÈ­ÇÏ¿© ¿À·¡µÈ À°¾Æ°¡ µÇ¸ç °á±¹Àº ¼¶À¯¼¼Æ÷¿Í ¾Æ±³Áú¼¶À¯·Î ±¸¼ºµÈ ¹ÝÈçÁ¶Á÷À¸·Î º¯ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • crude survival rate
    º¸Åë»ýÁ¸À², Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • disease free survival
    ¹«º´»ýÁ¸
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • survival
    »ýÁ¸
  • survival analysis
    »ýÁ¸ºÐ¼®
  • survival curve
    »ýÁ¸°î¼±
  • survival function
    »ýÁ¸ÇÔ¼ö
  • survival rate
    »ýÁ¸À²
  • survival ratio
    »ýÁ¸ºñ
  • survival ration
    ±¸¸í½Ä·®
  • survival time
    »ýÁ¸±â°£
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival analysis
    »ýÁ¸ºÐ¼®
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
  • survival curve
    »ýÁ¸°î¼±
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
  • survival rate
    »ýÁ¸·ü
  • survival
    »ýÁ¸
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival time
    »ýÁ¸±â°£
  • tissue plasminogen activator
    Á¶Á÷Çö󽺹̳ë°ÕȰ¼ºÁ¦
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • tissue
    Á¶Á÷
  • adipose tissue
    Áö¹æÁ¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
  • elastic tissue
    ź·ÂÁ¶Á÷
  • erectile tissue
    ¹ß±âÁ¶Á÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival analysis
    »ýÁ¸ºÐ¼®
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • survival curve
    »ýÁ¸°î¼±
  • disease free survival
    ¹«º´»ýÁ¸
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • forward survival
    ÇâÈÄ»ýÁ¸
  • survival function
    »ýÁ¸ÇÔ¼ö
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í°Ë»ç
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • survival rate
    »ýÁ¸À²
  • survival ratio
    »ýÁ¸ºñ
  • survival ration
    ±¸¸í½Ä·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • platelet survival measurement
    Ç÷¼ÒÆÇ»ýÁ¸´ÉÃøÁ¤
  • probability of survival
    »ýÁ¸(È®)·ü(Ë×Ì¡ Ì·Ëô).
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í½ÃÇè(îåúìϹáøÙ¤ãËúÐ).
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • Connetive tissue
    °áÇÕÁ¶Á÷(Ì¿ùêðÚòÄ)
  • Macrophages tissue
    ´ë½Ä¼¼Æ÷Á¶Á÷(ÓÞãÝá¬øàðÚòÄ)
  • abnormality of tissue
    Á¶Á÷ÀÌ»ó
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • adipose tissue disease
    Áö¹æÁ¶Á÷Áúȯ.
  • angioblastic tissue
    Ç÷°ü¹ß»ýÁ¶Á÷
  • free water in stationary tissue
    Á¤Àû Á¶Á÷³» ÀÚÀ¯ ¼öºÐ
  • general connective tissue
    ÀϹݰáÇÕÁ¶Á÷.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • spongy bone tissue [trabecular bone tissue]
    ÇØ¸é»ÀÁ¶Á÷
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • cell survival curve
    ¼¼Æ÷»ýÁ¸°î¼±
  • combat survival
    ÀüÅõ»ýÁ¸(¡­ßæðí).
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • desert survival
    »ç¸·»ýÁ¸(Ë×ËÎË×Ì¡).
  • disease free survival
    ¹«º´»ýÁ¸
  • erythrocyte survival
    ÀûÇ÷±¸»ýÁ¸
  • five year survival rate
    5³â»ýÁ¸À².
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • jungle survival
    Á¤±Û»ýÁ¸(¡­ßæðí).
  • life-table method of survival estimation
    »ý¸íÇ¥¹ý(»ýÁ¸ ÃßÁ¤ ¹æ¹ý)
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£(̰˻Ë×Ì¡Ëà˧).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Spongy bone tissue [Trabecular bone tissue]
    ÇØ¸é»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ÇØ¸é°ñÁ¶Á÷
  • Skeletal muscular tissue
    °¡·Î¹«´Ì±ÙÀ°Á¶Á÷ [»À´ë±ÙÀ°Á¶Á÷]
    [¿¾ ¿ë¾î] °ñ°Ý±ÙÁ¶Á÷
  • Brown fat tissue
    °¥»öÁö¹æÁ¶Á÷
    [¿¾ ¿ë¾î] °¥»öÁö¹æÁ¶Á÷
  • Subconjunctival tissue
    °á¸·¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] °á¸·ÇÏÁ¶Á÷
  • Lymphoblastic tissue
    ¸²ÇÁ°ü¹ß»ýÁ¶Á÷
    [¿¾ ¿ë¾î] ÀÓÆÄ¸ð¼¼Æ÷Á¶Á÷
  • Smooth musclular tissue
    ¹Î¹«´Ì±ÙÀ°Á¶Á÷ [³»Àå±ÙÀ°Á¶Á÷]
    [¿¾ ¿ë¾î] ÆòȰ±ÙÁ¶Á÷
  • White fat tissue
    ¹é»öÁö¹æÁ¶Á÷
    [¿¾ ¿ë¾î] ¹é»öÁö¹æÁ¶Á÷
  • Loose collagenous connective tissue
    ¼º±ä¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼Ò¼º°áÇÕÁ¶Á÷
  • Reticular connective tissue
    ¼¼¸Á°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼¸Á°áÇÕÁ¶Á÷
  • Reticular tissue
    ¼¼¸ÁÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼¸ÁÁ¶Á÷
  • Cellular connective tissue
    ¼¼Æ÷¼º°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼Æ÷¼º°áÇÕÁ¶Á÷
  • Neural crest tissue
    ½Å°æ´É¼±Á¶Á÷
    [¿¾ ¿ë¾î] ½Å°æ¸ªÁ¶Á÷
  • Tissue of neural crest (Mesectoderm)
    ½Å°æ´É¼±Á¶Á÷ (Áß°£¿Ü¹è¿±)
    [¿¾ ¿ë¾î] ½Å°æ¸ªÁ¶Á÷
  • Nervous tissue (Neuroblastoma)
    ½Å°æÁ¶Á÷ (½Å°æ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½Å°æÁ¶Á÷
  • Cardiac muscular tissue
    ½ÉÀå±ÙÀ°Á¶Á÷
    [¿¾ ¿ë¾î] ½É±ÙÁ¶Á÷
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bilharzial granulation tissue
    ¹æ±¤ÁÖÇ÷ÈíÃæÀ°¾ÆÁ¶Á÷
  • tissue parasite
    Á¶Á÷±â»ýÃæ
  • tissue selectivity
    Á¶Á÷¼±Åüº
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exponential survival curve
    Áö¼ö »ýÁ¸ °î¼± (ò¦â¦ßæðíÍØàÊ)
  • survival curve
    »ýÁ¸°î¼± (ßæðíÍØàÊ)
  • adipose tissue
    Áö¹æÁ¶Á÷(ò·Û¸ðÚòÄ)
  • brown adipose tissue
    °¥»öÁö¹æÁ¶Á÷(Êèßäò·Û¸ðÚòÄ)
  • established tissue chluture
    ¼ö¸³ Á¶Á÷¹è¾ç (â§Ø¡ðÚòÄÛÆå×)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • primary tissue culture
    ÀÏÂ÷ Á¶Á÷¹è¾ç(ìéó­ðÚòÄÛÆå×)
  • tissue culture
    Á¶Á÷¹è¾ç (ðÚòÄÛÆå×)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
  • tissue factor
    Á¶Á÷ÀÎÀÚ (ðÚòÄì×í­)
  • tissue hormone
    Á¶Á÷(ðÚòÄ)È£¸£¸ó
  • tissue plasminogen activator
    Á¶Á÷(ðÚòÄ)Çö󽺹̳ëÀü Ȱ¼ºÀÚ (üÀàõí­)
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
  • tissue slice
    Á¶Á÷ õ¿± (ðÚòÄô¼ç¨)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival
    »ýÁ¸
  • aberrant breast tissue
    ¹ÌÀÔÀ¯¹æÁ¶Á÷
  • areolar tissue
    À±¹®»óÁ¶Á÷
  • connective tissue
    °áÇÕÁ¶Á÷
  • fibrous tissue
    ¼¶À¯¼ºÁ¶Á÷
  • flowing tissue
    À¯µ¿Á¶Á÷, ±â·ù¼ºÁ¶Á÷
  • free water in stationary tissue
    Á¤ÀûÁ¶Á÷³» ÀÚÀ¯¼öºÐ
  • granulation tissue
    À°¾ÆÁ¶Á÷
  • inflammatory tissue
    ¿°ÁõÁ¶Á÷
  • interstitial tissue
    °£ÁúÁ¶Á÷
  • lattice in stationary tissue
    Á¤ÀûÁ¶Á÷³»°ÝÀÚ
  • MALT(mucosa associated lymphoid tissue)
    Á¡¸·°ü·Ã¸²ÇÁÁ¶Á÷
  • mesenchymal tissue
    Áß°£¿±Á¶Á÷, °£¿±Á¶Á÷
  • muscle tissue
    ±ÙÀ°Á¶Á÷, ±ÙÁ¶Á÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CSR central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie...
ABCDES abnormal alignment, bones-periarticular osteoporosis, cartilage-joint space loss, deformities, margi...
TCID tissue culture infective dose; tissue culture inoculated dose
TCID50 median tissue culture infective dose; 50% tissue culture infective dose
5 YSR 5 Year Survival Rate
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CSS Cause specific survival
S D)--survival
DFS Disease free survival
DSS Disease specific survival
DDFS Distant disease-free survival
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • jungle survival
    Á¤±Û »ýÁ¸
  • survival
    »ýÁ¸
  • survival rate
    »ýÁ¸À²
  • aberrant breast tissue
    ¹ÌÀÔ À¯¹æ Á¶Á÷
  • absorptive tissue
    Èí¼ö Á¶Á÷
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • adenoid tissue
    ¾Æµ¥³ëÀ̵å Á¶Á÷
  • adipose tissue disease
    Áö¹æ Á¶Á÷ Áúȯ
  • bone tissue
    »À Á¶Á÷, °ñ Á¶Á÷
  • bony tissue
    °ñ¼º Á¶Á÷
  • border tissue movement
    º¯¿¬ Á¶Á÷ ¿îµ¿
  • calcified tissue
    ¼®È¸È­ Á¶Á÷
    ¼®È¸È­°¡ ÀϾ Á¶Á÷.
  • cartilage tissue
    ¿¬°ñ Á¶Á÷, ¹°··»À Á¶Á÷
    »À ¸»´Ü¿¡ Àִ ź·Â¼º ÀÖ´Â °áÇÕÁ¶Á÷À̸ç, »À Ç¥¸éÀ» ½Ñ´Ù. ÅÂ¾Æ °ñ°Ý, ´Á°ñ, ºñ Áß°Ý, ¿ÜÀÌ¿¡µµ Á¸Àç.
  • cellular connective tissue
    ¼¼Æ÷¼º °áÇÕ Á¶Á÷
    ¼¼Æ÷·Î »çÀ̰¡ ¿¬°áµÇ¾î ÀÖ´Â Á¶Á÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
tissue survival The span of viability of a tissue or an organ.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
median survival <statistics> Median means the middle value. An equal number of people live longer as die earlier than the median.
(16 Dec 1997)
cell survival The span of viability of a cell characterised by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
(12 Dec 1998)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
survival 1. A living or continuing longer than, or beyond the existence of, another person, thing, or event; an outliving.
2. Any habit, usage, or belief, remaining from ancient times, the origin of which is often unknown, or imperfectly known. "The close bearing of the doctrine of survival on the study of manners and customs." (Tylor) Survival of the fittest.
<biology> See Natural selection, under Natural.
Origin: From Survive.
Source: Websters Dictionary
(01 Mar 1998)
survival analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
(12 Dec 1998)
survival rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
(12 Dec 1998)
survival time The period elapsing between the completion or institution of any procedure and death, the life-span of biologically or physically marked erythrocytes or other cells.
(05 Mar 2000)
disease-free survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
(12 Dec 1998)
five year survival rate The proportion of patients still alive five years after a diagnosis or form of treatment is completed. Usually applied to statistics of survival of cancer patients, since after five years, recurrences are much less likely to occur.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
long-term survival <oncology> Term used to describe the survival of leukaemia patients who have been disease free for prolonged periods of time, usually at least five years. The chance of disease returning (relapse) decreases with time.
(13 Nov 1997)
adenoid tissue A structure found within the lymphatic system that consists of lymphocytes within a network of fibres.
(09 Oct 1997)
adipose tissue <anatomy> Connective tissue that has been specialised to store fat.
See: adipocyte.
(25 Jun 1999)
aerenchymous tissue A type of plant tissue in which cells are unusually large, resulting in large air spaces in the plant organ, such tissues are often referred to as spongy and usually provide increased buoyancy.
(09 Oct 1997)
areolar tissue Loose, irregularly arranged connective tissue that consists of collagenous and elastic fibres, a protein polysaccharide ground substance, and connective tissue cells (fibroblasts, macrophages, mast cells, and sometimes fat cells, plasma cells, leukocytes, and pigment cells).
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Tissue Survival - »õâ The span of viability of a tissue or an organ.
    Synonyms : Organ Viability, Tissue Viability, Survival, Organ, Survival, Tissue, Viability, Organ, Viability, Tissue
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival
    »ì¾Æ ³²À½
  • survival
    ÀÜÁ¸;»ì¾Æ³²À½;»ýÁ¸ÀÚ;ÀÜÁ¸¹°;¿¹ºÎÅÍÀÇ Ç³½À(½Å¾Ó)
  • tissue
    Á¶Á÷
  • cleansing tissue
    È­Àå¿ë ¹Ú¿±Áö(Ƽ½´ ÆäÀÌÆÛ)
  • connective tissue
    °áÇÕ Á¶Á÷
  • facial tissue
    °í±Þ È­ÀåÁö
  • permanent tissue
    ¿µ±¸ Á¶Á÷
  • tissue
    Á¶Á÷;¾ãÀº Á÷¹°;(°ÅÁþ¸» µûÀ§ÀÇ)µÚ¹ü¹÷;¿¬¼Ó;ź¼Ò ÀÎÈ­Áö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á